HIV 1 News and Research

RSS

Long-acting HIV prevention tools could help close the gap before a vaccine arrives

A review of non-vaccine HIV interventions highlights the strong preventive effects of long-acting PrEP, sustained ART, U=U, vertical transmission programs, and voluntary medical male circumcision. Gene editing and multispecific antibodies may expand future options, but safety, cost, access, adherence, and implementation barriers remain.

5 Aug 2026

Once-weekly oral tablet proves highly effective for HIV care

An international clinical trial led by researchers including Professor Chloe Orkin of Queen Mary University of London has shown that a once-weekly oral treatment for HIV is as effective as one of today's leading daily therapies, offering the potential for a new treatment option that could reduce the burden of lifelong daily pill-taking.

29 Jul 2026

AI-powered analytics and experimental validation: Transforming target identification in drug discovery

Discover how AI-powered analytics and experimental validation combine to improve target identification and accelerate drug discovery success.

From Axxam S.p.A 23 Jul 2026

New vaccines successfully boost frontline immune cells against HIV

T-cells are the immune system's frontline defenders with a crucial role in controlling HIV. In a milestone clinical trial published in the Journal of Clinical Investigation, researchers with the UNC Institute for Global Health and Infectious Diseases (IGHID) at the UNC School of Medicine have demonstrated that new vaccines can significantly boost T cells targeting the most vulnerable, conserved regions of HIV-areas considered key to effective immune control.

22 Jun 2026

Wastewater analysis offers novel approach to track HIV burden

Human immunodeficiency virus 1 (HIV-1) detection in wastewater offers a novel approach to monitor the virus in communities.

15 Jun 2026

Defective HIV copies explain persistent viral traces during treatment

Antiretroviral drugs for HIV infection have enabled most people living with the virus to live long and healthy lives.

8 Jun 2026

Study shows how HIV leads to chronic pain

Over half of the people carrying HIV experience chronic pain at some point, which is difficult to treat. In a new JNeurosci paper, Hui-Lin Pan, from The University of Texas MD Anderson Cancer Center, and colleagues used mice to explore how HIV leads to chronic pain.

1 Jun 2026

Rockefeller scientists reveal how HIV strains escape broadly neutralizing antibodies

Broadly neutralizing antibodies (bNAbs) are among the most promising new treatments for HIV, offering the potential to forego traditional daily dose of antiretroviral drugs.

11 May 2026

New discovery challenges a decades-old assumption in HIV biology

Researchers from Queen Mary University of London have uncovered a previously unknown mechanism by which HIV-1 can infect resting immune cells.

6 May 2026

Antiretroviral therapy reduces biological aging in people living with HIV

A major study presented today at ESCMID Global 2026 has found that antiretroviral therapy (ART) reduces accelerated biological ageing in people with HIV (PWH) by nearly four years, a finding that could transform how clinicians monitor HIV treatment and long-term health outcomes.

20 Apr 2026

Existing medication could improve the health of people living with HIV

HIV exhausts the body's immune system by overactivating it, despite effective antiviral treatment.

23 Mar 2026

Novel antibody 007 targets the elusive HIV envelope epitope

HIV-1 can be neutralized by antibodies which bind to vulnerable structures on the virus surface. One such vulnerable site is the so-called V3 glycan site of the viral envelope protein.

13 Feb 2026

Enhanced natural killer cells show promise for HIV remission

More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS).

5 Feb 2026

Single-dose HIV vaccine candidate induces neutralizing antibodies

Scientists at The Wistar Institute have developed an HIV vaccine candidate that achieves something never before observed in the field: inducing neutralizing antibodies against HIV after a single immunization in nonhuman primates.

3 Feb 2026

Genetic inheritance and life experience leave distinct epigenetic marks in immune cells

The COVID-19 pandemic gave us tremendous perspective on how wildly symptoms and outcomes can vary between patients experiencing the same infection.

29 Jan 2026

How DNA and life experiences leave distinct marks on the human immune system

Using single-cell epigenomic profiling of immune cells from 110 individuals, researchers show that genetic variation and environmental exposures shape the human immune system through distinct DNA methylation mechanisms. Genetic effects concentrate within gene bodies of memory cells, while environmental exposures primarily remodel regulatory regions in naive immune cells.

28 Jan 2026

Mcgill researchers find unexpected chemical contaminants in human milk samples

An interdisciplinary team including researchers at McGill University has found a range of unexpected chemical contaminants in human milk samples from Canada and South Africa.

20 Jan 2026

The challenge of tracking asymptomatic Mpox

The mpox virus appears to be circulating silently in parts of Nigeria, in many cases without the symptoms typically associated with the disease, according to new research led by scientists from the University of Cambridge and partners in Nigeria. The findings may have implications for controlling the spread of the disease.

20 Jan 2026

Cervical cancer association with unsafe sex and smoking

The study reveals deep inequalities in cervical cancer mortality linked to smoking and unsafe sex, highlighting the need for targeted prevention strategies.

15 Jan 2026

Immune dysfunction persists after combined TB and HIV therapy

The immune system remains seriously out-of-whack – in an inflammatory state of overactivation and impaired functionality – following the international gold standard for treating people with latent tuberculosis (TB) and HIV, a team at Texas Biomedical Research Institute reports in Nature Communications.

14 Jan 2026